GM-CSF has been shown by previous multiplex cytokine analyses to be critical in the early response and possible clearance of M. tuberculosis in humans and mice, so that the use of recombinant GM-CSF as an adjunctive therapy for TB has been posited; the findings of this study suggest that this may also be of benefit to feline patients. This evidence concerns the gene CSF2 and tuberculosis.